Tirzepatide

Product Name: Tirzepatide

Product source: Chemical synthesis (peptide solid-phase synthesis method)

Content specification: ≥ 99%

CAS number: 2023788-19-2

Detection method: HPLC

Active ingredient: The actual structure contains 39 amino acids and C20 fatty acid chains

Molecular formula: C ₂₂₅ H ∝₄₈ N ₅₀ O ₆₈

Molecular weight: 4813.5 Da

Product Description: White to off white freeze-dried powder or sponge like solid

Product use: raw materials for pharmaceutical preparations, scientific research purposes, and development of generic drugs

Product packaging: Sterile glass bottles (such as 2mL/5mL penicillin bottles), lined with rubber stoppers and sealed with aluminum-plastic caps.

Product specifications: Small sizes: 1mg, 2mg, 5mg, 10mg, 25mg (commonly used in research and development)

Large specifications: 100mg, 500mg, 1g (commonly used in production)

Product storage: unopened: -20 ° C ± 5 ° C, frozen, dark, dry storage (recommended for long-term stability).

Short term/transportation: 2-8 ° C refrigeration is acceptable (stability needs to be verified).

After reconstitution: Store according to the formulation requirements (usually refrigerated at 2-8 ° C, away from light, limited time use).

Shelf life: unopened freeze-dried powder: usually 24-36 months

Products Description

A Comprehensive Overview of High Purity Tilpotide

Tilpotide is a novel glucagon like peptide-1 receptor (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) dual channel agonist, administered once a week. GLP-1 and GIP both belong to enteropancreatin, which is a peptide secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing hypoglycemic effects. It can also delay gastric emptying and suppress appetite, thereby controlling weight; The latter has functions such as inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the action of GLP-1 receptor agonists.

Products Advantages

The following are the core advantages of Tirzepatide:

1. Dual target innovation, the world's first GIP/GLP-1 receptor dual agonist, simultaneously activates two types of enteropancreatin pathways, producing synergistic hypoglycemic and weight loss effects, with a mechanism leading single target GLP-1 drugs (such as semaglutide).

2. Significant effect

3. Cardiovascular protection

4. Simultaneously improve metabolic indicators such as blood lipids, blood pressure, and fatty liver, and reduce the risk of multiple complications.

5. Long term convenience

 Products Efficacy

The following is the core efficacy of Tirzepatide:

1. Treatment of type 2 diabetes

2. Obesity/Overweight Management

3. Reduced cardiovascular risk

4. Potential expanded indications (currently under development)

Products Application

The following are the core applications of Tirzepatide:

1. Medical aspect

2. In terms of scientific research